Doctor of Philosophy / Department of Biochemistry / Ramaswamy Krishnamoorthi / Insect [beta]-1,3-glucan recognition protein ([beta]GRP), a soluble receptor in the hemolymph, binds to the surfaces of bacteria and fungi and activates serine protease cascades that promote destruction of pathogens by means of melanization or expression of antimicrobial peptides. Delineation of mechanistic details of these processes may help develop strategies to control insect-borne diseases and economic losses. Multi-dimensional nuclear magnetic resonance (NMR) techniques were employed to solve the solution structure of the Indian meal moth (Plodia interpunctella) [beta]GRP N-terminal domain (N-[beta]GRP), which is sufficient to activate the prophenoloxidase (proPO) pathway resulting in melanin formation. This is the first determined three-dimensional structure of N-[beta]GRP, which adopts an immunoglobulin fold. Addition of laminarin, a [beta]-1,3 and [beta]-1,6 link-containing glucose polysaccharide (∼6 kDa) that activates the proPO pathway, to N-[beta]GRP results in the loss of NMR cross-peaks from the backbone [subscript]1[subscript]5N-[subscript]1H groups of the protein, suggesting the formation of a large complex. Analytical ultracentrifugation (AUC) studies of formation of the N-[beta]GRP:laminarin complex show that ligand binding induces self-association of the protein-carbohydrate complex into a macro structure, likely containing six protein and three laminarin molecules (∼102 kDa). The macro complex is quite stable, as it does not undergo dissociation upon dilution to submicromolar concentrations. The structural model thus derived from this study for the N-[beta]GRP:laminarin complex in solution differs from the one in which a single N-[beta]GRP molecule has been proposed to bind to a triple-helical form of laminarin on the basis of a X-ray crystal structure of the N-[beta]GRP:laminarihexaose complex. AUC studies and phenoloxidase activation measurements made with designed mutants of N-[beta]GRP indicate that electrostatic interactions between the ligand-bound protein molecules contribute to the stability of the N-[beta]GRP:laminarin complex and that a decreased stability results in a reduction of proPO activation. These novel findings suggest that ligand-induced self-association of the [beta]GRP:[beta]-1,3-glucan complex may form a platform on a microbial surface for recruitment of downstream proteases, as a means of amplification of the pathogen recognition signal. In the case of the homolog of GNBPA2 from Anopheles gambiae, the malaria-causing Plasmodium carrier, multiligand specificity was characterized, suggesting a functional diversity of the immunoglobulin domain structure.

A Criptococose é uma enfermidade micótica sistêmica, subaguda ou crônica, que acomete a cavidade nasal, tecidos paranasais e pulmões do homem, animais domésticos e silvestres, podendo disseminar-se para o sistema nervoso central, olhos, pele e outros órgãos. Considerando as dificuldades terapêuticas no tratamento da micose em pequenos animais, incluindo toxicidade, desenvolvimento de resistência aos antifúngicos tradicionalmente utilizados e longos períodos de tratamento da enfermidade, o estudo objetivou avaliar a eficácia do imunomodulador ß (1-3) glucana isoladamente e em associação ao fluconazol no tratamento da criptococose experimental. Foram utilizados 100 camundongos (Mus musculus), cepa UFPel, albinos, os quais foram divididos em cinco grupos de 20 animais. O tratamento dos animais com criptococose experimental foi iniciado sete dias após a inoculação. O grupo Controle (G1) foi tratado com 0,1 ml de água destilada estéril, o grupo Fluconazol (G2) com 5 mg/kg de fluconazol, o grupo Fluconazol associado a ß (1-3) glucana (G3) com 5 mg/kg de fluconazol associado a 0,5 mg de ß (1-3) glucana, o grupo Glucana dose I (G4) com 0,5 mg de ß (1-3) glucana e o grupo Glucana dose II (G5) recebeu 0,25 mg de ß (1-3) glucana. Após acompanhamento clínico durante as seis semanas de tratamento os animais foram eutanasiados e necropsiados para avaliação anatomopatológica dos órgãos, quantificação das unidades formadoras de colônias fúngicas (UFCs), retroisolamento e avaliação histopatológica. Nas avaliações clínicas o G3 foi sempre superior ao G1 e G2, sendo que na última avaliação clínica individual, os animais pertencentes ao G3 não apresentavam nenhum sintoma clínico. O G2 teve um menor número de órgãos afetados e de alterações macroscópicas, seguido pelo G3, sendo que no primeiro não foram observadas lesões em órgãos-alvo, como pulmão e cérebro. O grupo com maior número de lesões e órgãos afetados foi o G1. Nos parâmetros retroisolamento e UFCs, o G3 foi superior aos outros tratamentos, seguido pelo G2, sendo que o pior grupo, ou seja, aquele que teve um maior número de isolamentos e maior quantificação de UFCs foi o G1. Conforme os resultados obtidos os tratamentos G2 e G3 foram os mais eficazes para a remissão da criptococose experimental, no entanto, G3 apresentou uma superioridade na maioria dos parâmetros avaliados. Portanto, de acordo com os resultados obtidos, a associação de fluconazol ao imunomodulador ß (1-3) glucana pode ser uma alternativa benéfica em considerável quantidade de pacientes com criptococose. / Cryptococcosis is a systematic sub acute or chronic mycotic condition that affects the nasal cavity, paranasal tissues and the lungs of humans, as well as domestic and wild animals, which can spread to the central nervous system, skin, and other organs. Considering the therapeutic difficulties in treating this mycosis in small animals, which include toxicity, resistance towards traditionally used antifungals, and the extended treatment of this condition, this study aimed to evaluate the ß (1-3) glucan immunomodulator efficacy when used both alone and in association with fluconazole in the treatment of experimental cryptococcosis. One Hundred albino UFPel strain mice (Mus musculus), divided into five groups of 20 animals each, were used. The treatment of these animals with experimental cryptococcosis was started seven days following inoculation. The control group (G1) was treated with 0,1 ml sterile distilled water. The fluconazole group (G2) was treated with 5 mg/kg fluconazole; the fluconazole associated with ß glucan (1-3) group (G3) was treated with 5 mg/kg fluconazole associated with 0,5 mg ß (1-3) glucan ; the group glucan dose I (G4) was treated with 0,5 mg ß (1-3) glucan, and the group glucan dose II (G5) was administered 0,25 mg ß (1-3) glucan. After the six-week treatment clinical follow-up, the aimals were euthanized and necropsied for anatomopathological evaluation of organs, quantification of fungal colony-forming units (FCUs), retro isolation and histopathological evaluation. In clinical evaluations, G3 was always superior to G1 and G2, and in the last individual clinical evaluation, G3 animals did not show any clinical symptoms. G2 had a smaller number of affected organs and microscopic alterations, followed by G3. In G2, target organ lesions, such as those in the lungs and brain, were not found. Considering retro isolation and FCU parameters, G3 was superior to other treatments, followed by G2; the worst group, that is, the one with the highest isolation occurrence and greatest FCU quantification, was G1. According to the results obtained, treatments G2 and G3 were the most efficient in experimental cryptococcosis remission; however, G3 was superior in most parameters evaluated. Therefore, according to the results obtained, the association of fluconazole with the ß (1-3) glucan immunomodulator can be a beneficial alternative to a considerable number of cryptococcosis-bearing patients.

A Criptococose é uma enfermidade micótica sistêmica, subaguda ou crônica, que acomete a cavidade nasal, tecidos paranasais e pulmões do homem, animais domésticos e silvestres, podendo disseminar-se para o sistema nervoso central, olhos, pele e outros órgãos. Considerando as dificuldades terapêuticas no tratamento da micose em pequenos animais, incluindo toxicidade, desenvolvimento de resistência aos antifúngicos tradicionalmente utilizados e longos períodos de tratamento da enfermidade, o estudo objetivou avaliar a eficácia do imunomodulador ß (1-3) glucana isoladamente e em associação ao fluconazol no tratamento da criptococose experimental. Foram utilizados 100 camundongos (Mus musculus), cepa UFPel, albinos, os quais foram divididos em cinco grupos de 20 animais. O tratamento dos animais com criptococose experimental foi iniciado sete dias após a inoculação. O grupo Controle (G1) foi tratado com 0,1 ml de água destilada estéril, o grupo Fluconazol (G2) com 5 mg/kg de fluconazol, o grupo Fluconazol associado a ß (1-3) glucana (G3) com 5 mg/kg de fluconazol associado a 0,5 mg de ß (1-3) glucana, o grupo Glucana dose I (G4) com 0,5 mg de ß (1-3) glucana e o grupo Glucana dose II (G5) recebeu 0,25 mg de ß (1-3) glucana. Após acompanhamento clínico durante as seis semanas de tratamento os animais foram eutanasiados e necropsiados para avaliação anatomopatológica dos órgãos, quantificação das unidades formadoras de colônias fúngicas (UFCs), retroisolamento e avaliação histopatológica. Nas avaliações clínicas o G3 foi sempre superior ao G1 e G2, sendo que na última avaliação clínica individual, os animais pertencentes ao G3 não apresentavam nenhum sintoma clínico. O G2 teve um menor número de órgãos afetados e de alterações macroscópicas, seguido pelo G3, sendo que no primeiro não foram observadas lesões em órgãos-alvo, como pulmão e cérebro. O grupo com maior número de lesões e órgãos afetados foi o G1. Nos parâmetros retroisolamento e UFCs, o G3 foi superior aos outros tratamentos, seguido pelo G2, sendo que o pior grupo, ou seja, aquele que teve um maior número de isolamentos e maior quantificação de UFCs foi o G1. Conforme os resultados obtidos os tratamentos G2 e G3 foram os mais eficazes para a remissão da criptococose experimental, no entanto, G3 apresentou uma superioridade na maioria dos parâmetros avaliados. Portanto, de acordo com os resultados obtidos, a associação de fluconazol ao imunomodulador ß (1-3) glucana pode ser uma alternativa benéfica em considerável quantidade de pacientes com criptococose. / Cryptococcosis is a systematic sub acute or chronic mycotic condition that affects the nasal cavity, paranasal tissues and the lungs of humans, as well as domestic and wild animals, which can spread to the central nervous system, skin, and other organs. Considering the therapeutic difficulties in treating this mycosis in small animals, which include toxicity, resistance towards traditionally used antifungals, and the extended treatment of this condition, this study aimed to evaluate the ß (1-3) glucan immunomodulator efficacy when used both alone and in association with fluconazole in the treatment of experimental cryptococcosis. One Hundred albino UFPel strain mice (Mus musculus), divided into five groups of 20 animals each, were used. The treatment of these animals with experimental cryptococcosis was started seven days following inoculation. The control group (G1) was treated with 0,1 ml sterile distilled water. The fluconazole group (G2) was treated with 5 mg/kg fluconazole; the fluconazole associated with ß glucan (1-3) group (G3) was treated with 5 mg/kg fluconazole associated with 0,5 mg ß (1-3) glucan ; the group glucan dose I (G4) was treated with 0,5 mg ß (1-3) glucan, and the group glucan dose II (G5) was administered 0,25 mg ß (1-3) glucan. After the six-week treatment clinical follow-up, the aimals were euthanized and necropsied for anatomopathological evaluation of organs, quantification of fungal colony-forming units (FCUs), retro isolation and histopathological evaluation. In clinical evaluations, G3 was always superior to G1 and G2, and in the last individual clinical evaluation, G3 animals did not show any clinical symptoms. G2 had a smaller number of affected organs and microscopic alterations, followed by G3. In G2, target organ lesions, such as those in the lungs and brain, were not found. Considering retro isolation and FCU parameters, G3 was superior to other treatments, followed by G2; the worst group, that is, the one with the highest isolation occurrence and greatest FCU quantification, was G1. According to the results obtained, treatments G2 and G3 were the most efficient in experimental cryptococcosis remission; however, G3 was superior in most parameters evaluated. Therefore, according to the results obtained, the association of fluconazole with the ß (1-3) glucan immunomodulator can be a beneficial alternative to a considerable number of cryptococcosis-bearing patients.

A Criptococose é uma enfermidade micótica sistêmica, subaguda ou crônica, que acomete a cavidade nasal, tecidos paranasais e pulmões do homem, animais domésticos e silvestres, podendo disseminar-se para o sistema nervoso central, olhos, pele e outros órgãos. Considerando as dificuldades terapêuticas no tratamento da micose em pequenos animais, incluindo toxicidade, desenvolvimento de resistência aos antifúngicos tradicionalmente utilizados e longos períodos de tratamento da enfermidade, o estudo objetivou avaliar a eficácia do imunomodulador ß (1-3) glucana isoladamente e em associação ao fluconazol no tratamento da criptococose experimental. Foram utilizados 100 camundongos (Mus musculus), cepa UFPel, albinos, os quais foram divididos em cinco grupos de 20 animais. O tratamento dos animais com criptococose experimental foi iniciado sete dias após a inoculação. O grupo Controle (G1) foi tratado com 0,1 ml de água destilada estéril, o grupo Fluconazol (G2) com 5 mg/kg de fluconazol, o grupo Fluconazol associado a ß (1-3) glucana (G3) com 5 mg/kg de fluconazol associado a 0,5 mg de ß (1-3) glucana, o grupo Glucana dose I (G4) com 0,5 mg de ß (1-3) glucana e o grupo Glucana dose II (G5) recebeu 0,25 mg de ß (1-3) glucana. Após acompanhamento clínico durante as seis semanas de tratamento os animais foram eutanasiados e necropsiados para avaliação anatomopatológica dos órgãos, quantificação das unidades formadoras de colônias fúngicas (UFCs), retroisolamento e avaliação histopatológica. Nas avaliações clínicas o G3 foi sempre superior ao G1 e G2, sendo que na última avaliação clínica individual, os animais pertencentes ao G3 não apresentavam nenhum sintoma clínico. O G2 teve um menor número de órgãos afetados e de alterações macroscópicas, seguido pelo G3, sendo que no primeiro não foram observadas lesões em órgãos-alvo, como pulmão e cérebro. O grupo com maior número de lesões e órgãos afetados foi o G1. Nos parâmetros retroisolamento e UFCs, o G3 foi superior aos outros tratamentos, seguido pelo G2, sendo que o pior grupo, ou seja, aquele que teve um maior número de isolamentos e maior quantificação de UFCs foi o G1. Conforme os resultados obtidos os tratamentos G2 e G3 foram os mais eficazes para a remissão da criptococose experimental, no entanto, G3 apresentou uma superioridade na maioria dos parâmetros avaliados. Portanto, de acordo com os resultados obtidos, a associação de fluconazol ao imunomodulador ß (1-3) glucana pode ser uma alternativa benéfica em considerável quantidade de pacientes com criptococose. / Cryptococcosis is a systematic sub acute or chronic mycotic condition that affects the nasal cavity, paranasal tissues and the lungs of humans, as well as domestic and wild animals, which can spread to the central nervous system, skin, and other organs. Considering the therapeutic difficulties in treating this mycosis in small animals, which include toxicity, resistance towards traditionally used antifungals, and the extended treatment of this condition, this study aimed to evaluate the ß (1-3) glucan immunomodulator efficacy when used both alone and in association with fluconazole in the treatment of experimental cryptococcosis. One Hundred albino UFPel strain mice (Mus musculus), divided into five groups of 20 animals each, were used. The treatment of these animals with experimental cryptococcosis was started seven days following inoculation. The control group (G1) was treated with 0,1 ml sterile distilled water. The fluconazole group (G2) was treated with 5 mg/kg fluconazole; the fluconazole associated with ß glucan (1-3) group (G3) was treated with 5 mg/kg fluconazole associated with 0,5 mg ß (1-3) glucan ; the group glucan dose I (G4) was treated with 0,5 mg ß (1-3) glucan, and the group glucan dose II (G5) was administered 0,25 mg ß (1-3) glucan. After the six-week treatment clinical follow-up, the aimals were euthanized and necropsied for anatomopathological evaluation of organs, quantification of fungal colony-forming units (FCUs), retro isolation and histopathological evaluation. In clinical evaluations, G3 was always superior to G1 and G2, and in the last individual clinical evaluation, G3 animals did not show any clinical symptoms. G2 had a smaller number of affected organs and microscopic alterations, followed by G3. In G2, target organ lesions, such as those in the lungs and brain, were not found. Considering retro isolation and FCU parameters, G3 was superior to other treatments, followed by G2; the worst group, that is, the one with the highest isolation occurrence and greatest FCU quantification, was G1. According to the results obtained, treatments G2 and G3 were the most efficient in experimental cryptococcosis remission; however, G3 was superior in most parameters evaluated. Therefore, according to the results obtained, the association of fluconazole with the ß (1-3) glucan immunomodulator can be a beneficial alternative to a considerable number of cryptococcosis-bearing patients.

Using various synthetic strategies, we designed several libraries of novel polysaccharide mixed ester derivatives for oral drug delivery applications. Cellulose and cellulose esters have been extensively studied and utilized for different applications such as separation membranes, sustainable plastics, and enteric coatings in oral drug delivery carriers. We sought to exploit the ring-opening of cyclic anhydrides, succinic and glutaric anhydride, to append ω-carboxyl groups to commercially available cellulose and cellulose ester substrates. We used scalable synthetic strategies and widely available and cheap reagents to show a proof-of-concept for the manufacturability of these different polymer derivatives. We incorporated different degrees of substitution of ω-carboxyl groups to impart a range of water solubility in these polymers. The derivatives displayed excellent <i>T</i>g values for ASD applications, adequate water solubility, and good amphiphilic properties. We designed very effective amorphous solid dispersion (ASD) oral drug delivery polymers that prevented recrystallization of felodipine for hours and had excellent congruent polymer-drug release from the formulation at 20% drug loading. During the ring-opening reactions of the cellulose derivatives with glutaric anhydride we discovered that crosslinking and gelation can occur, especially with cellulose and cellulose ester substrates with a high degree of substitution (DS) of hydroxy groups. We isolated and characterized these gelled products using rheology, and solid-state 1D and 2D NMR spectroscopy, to evaluate whether the gels are physical or chemical in nature and proposed a mechanism for gelation. We determined that the gels are mostly physical but can proceed to chemical crosslinking over time. We designed a library of cellulose ester derivatives, and we investigated their performance as amorphous solid dispersion (ASD) drug delivery vehicles for the lipophilic drug felodipine, through <i>in vitro</i> experiments. Aside from felodipine, many other active pharmaceutical ingredients (APIs) are also highly crystalline and poorly water-soluble. ASDs are used to disrupt the crystalline packing of these drugs through dispersing them in amorphous polymeric carriers, facilitating their water-solubility, and preventing their recrystallization. We showed that our polymers performed remarkably well in the <i>in vitro</i> studies and inhibited crystallization of model compound felodipine for several hours while providing optimal drug release, affording highly promising ASD polymers. If company formulators are unable to develop an effective oral-delivery carrier to prevent a drug from recrystallizing, then the drug cannot be tested in <i>in vivo</i> toxicology studies, and therefore cannot be brought to market because of its poor aqueous solubility and subsequent low bioavailability. To test the robustness of our polymers, we also performed <i>in vitro</i> ASD experiments at the pharmaceutical company AbbVie with their most rapidly crystallizing pipeline compounds, and several commercially available drugs (Compound A, axitinib, and ziprasidone). We demonstrated that our polymers could also prevent drug recrystallization with these rapid crystallizers, outperforming commercial polymers like FDA-approved hydroxypropyl methyl cellulose acetate succinate (HPMCAS (MF)), even at exceptionally high drug loading ratios of 40 times the concentration of polymer. α-1,3-Glucans are an emerging class of polysaccharides and are structurally different than cellulose due to their α (1→3) linkage versus the cellulose β (1→4) glycosidic linkage. We demonstrated that we could modify these derivatives using a variety of esterification strategies and TEMPO-mediated C6 selective oxidation, affording a myriad of different novel polymer products, some of which are structural analogs of the cellulose ester derivatives we previously created. The polymers had higher <i>T</i>g values than the cellulose ester polymers, which may be useful for applications where heat resistance is desired. In the future, we will screen some of these α-1,3-glucan derivatives with poorly water-soluble enzalutamide, posaconazole and celecoxib model drugs, to evaluate their crystallization inhibition properties and the influence of polymer morphology upon structure-property relationships. We expect that these synthetic polymer strategies will offer scalable routes to novel ASD polymers, which we demonstrated to be highly effective drug crystallization inhibitors against a variety of different hydrophobic pharmaceutical compounds. / Doctor of Philosophy / Polysaccharides are polymers comprised of many linked sugar molecules and are an incredibly abundant and renewable resource. They are found everywhere in nature such as the wood from trees, the shells of crabs, the exoskeletons of bugs, and the mushrooms that sprout in damp forests. The research in this dissertation focuses on the use and chemical modification of polysaccharides for designing new, polysaccharide-based oral drug delivery systems called amorphous solid dispersions (ASDs), which significantly aid in the solubility and bioavailability of important medications. We started with the chemical modification of cellulose, the most abundant plant polysaccharide on planet Earth, and previously modified commercial cellulose substrates (known as cellulose esters) to create novel polymers for ASDs. We successfully modified these polymers, characterized them, and evaluated their potential as oral drug delivery vehicles by formulating them with several different classes of potent drugs used to treat a variety of diseases such as hypertension and schizophrenia. We showed that our designed cellulose ester polymers kept these hydrophobic drugs water-soluble for long-enough so that they can be adequately absorbed in the human body through the gastrointestinal tract, significantly outperforming commercial polymers in many cases. During the chemical modification of the cellulose esters, we also observed that they were prone to form gels, and we investigated this gelation phenomena in more detail through rheometry, 1D and 2D solid-state nuclear magnetic resonance spectroscopy (similar in principle to the medical diagnostic method, magnetic resonance imaging or MRI). We discovered that these gels can be physically and/or chemically linked together, and that different gelation mechanisms can dominate depending on the polysaccharide substrate and the esterification reagent used. We extended our research to other polysaccharide derivatives called α-1,3-glucans, which can be sourced from fungi, and/or enzymatically synthesized in the lab. Using various synthetic esterification and oxidation chemical methods to functionalize this polysaccharide, we designed a library of entirely novel polymers with different physical structures relative to the cellulose ester polymers. The polymers displayed thermal properties that show promise in drug delivery vehicle applications and in applications where high heat resistance is required. Overall, we developed next-generation polymers for amorphous solid dispersion oral drug delivery applications. We displayed the versatility of using a select few chemistry strategies to create a variety of different polymers with very different physicochemical properties. We hope that this work will help researchers design sustainable, plant-based polymers for ASD applications and we hope to nurture future structure-function studies to improve ASD performance for the benefit of patients in need.

Submitted by ANGELICA AUGUSTA GRIGOLI DOMINATO null (angelica@unoeste.br) on 2017-02-16T18:51:51Z No. of bitstreams: 1 Angélica A. Grigoli Dominato.pdf: 4485568 bytes, checksum: 4abc8fe39b8c64a5ed8be37f2be077de (MD5) / Approved for entry into archive by LUIZA DE MENEZES ROMANETTO (luizamenezes@reitoria.unesp.br) on 2017-02-20T20:26:27Z (GMT) No. of bitstreams: 1 dominato_aag_dr_sjrp.pdf: 4485568 bytes, checksum: 4abc8fe39b8c64a5ed8be37f2be077de (MD5) / Made available in DSpace on 2017-02-20T20:26:27Z (GMT). No. of bitstreams: 1 dominato_aag_dr_sjrp.pdf: 4485568 bytes, checksum: 4abc8fe39b8c64a5ed8be37f2be077de (MD5) Previous issue date: 2017-01-20 / A atividade metabólica fúngica, especialmente nos endofíticos, favorece a secreção de moléculas como antibióticos, pigmentos, enzimas e polissacarídeos, que podem ser aplicadas nas indústrias alimentícia, cosmética, farmacêutica, entre outras. A diversidade química dos exopolissacarídeos (EPS) bem como a possibilidade de sua utilização como substrato para diferentes modificações químicas (carboxilação, sulfatação e metilação) aumentam seu espectro de aplicação. Realizar o cultivo submerso dos fungos endofíticos Neofusicoccum parvum, Fusarium sp e Colletotrichum gloeosporioides para a produção de EPS foi o primeiro objetivo deste trabalho. Uma vez obtidos, os EPS foram purificados e quimicamente caracterizados. Sulfatação e ensaio da atividade anticoagulante foram realizados. Os parâmetros concentração de inóculo e tempo de cultivo foram estabelecidos para maior produção dos EPS, por fermentação submersa. Etapas de purificação, por centrifugação, foram efetuadas após análises por cromatografia de exclusão estérica a alta pressão, com detecção por índice de refração (HPSEC/RID). Os EPS purificados [precipitado do C. gloeosporioides (C. gloeosporioidesprec) e os três sobrenadantes] mostraram-se praticamente isentos de proteínas. A hidrólise ácida e subsequente análise dos hidrolisados por cromatografia de troca aniônica a alta pressão com detecção por amperometria pulsada (HPAEC/PAD) indicaram que apenas o C. gloeosporioidesprec era uma glucana. A análise por cromatografia gasosa acoplada à espectrometria de massa (GC/MS) mostrou um único derivado, 1,3,5 tri-O-acetil, 2,4,6-tri-O-metil glucitol com fragmentos de massa (m/z 118, 161, 203, 234.1) condizente com uma glucana do tipo (1→3). Os espectros de FT-IR apresentaram sinais na região de impressão digital, 926 cm-1 e 820 cm-1, típicos de polissacarídeos em configuração . Esses resultados foram confirmados por ressonância magnética nuclear bidimensional (HSQC), com um único acoplamento C1/H1, em 99,3/5,18 ppm e um sinal deslocado para campo baixo, 82,8/3,74 ppm, característico de C-3 substituído, indicando que o EPS é uma α-(1→3)-glucana. A sulfatação desta molécula resultou em α-(1→3)-D-glucanasulf com DS de 0,75 que foi utilizada nos ensaios de atividade anticoagulante. O aumento do tempo para a coagulação, nos testes do APTT (Tempo de Tromboplastina Parcial Ativada) e TT (Tempo de Trombina), foi concentração-dependente, indicando que [α-(1→3)-D-glucanasulf] pode atuar como um inibidor da via intrínseca da coagulação sanguínea e da conversão do fibrinogênio em fibrina, caracterizando-a como um potencial anticoagulante. / Fungal metabolic activity, especially in the endophytic, favors secretion of molecules such as antibiotics, pigments, enzymes and polysaccharides, which can be applicable by food, cosmetic and pharmaceutical industries, and others. The chemical diversity of the exopolysaccharides (EPS), as well as the possibility of their use as substrate for different chemical modifications (carboxylation, sulfation and methylation) increases their application spectrum. Submerged cultivation of the endophytic fungi Neofusicoccum parvum, Fusarium sp and Colletotrichum gloeosporioides for the production of EPS was the first aim of this study. Once the EPS were obtained, they were purified and chemically characterized. Chemical modification by sulfation and anticoagulant activity assays were performed. Cultivation to obtain EPS were performed in submerged fermentation. The inoculum concentration and incubation time parameters were set in order to obtain a higher amount of EPS. Purification by centrifugation was performed after analysis by high pressure steric exclusion chromatography with refractive index detection (HPSEC / RID). Purified EPS [precipitate of C. gloeosporioides (C. gloeosporioidesprec) and the three supernatants] proved to be virtually free of protein polysaccharides. Acid hydrolysis and subsequent analysis of the hydrolysates with high performance anionic exchange chromatography with amperometric detection (HPAEC/PAD) indicated that only the C. gloeosporioidesprec was a glucan. Analysis from gas chromatography and mass spectrometry showed a single derivative, 1,3,5-tri-Oacetyl, 2,4,6-tri-O-methyl glucitol with mass fragments (m/z 118, 161, 203, 234.1) consistent with a (1→3)-glucan. FT-IR spectra showed absorption bands typical from carbohydrate and signals in the digital region at 926 cm-1 and 820 cm-1, typical of polysaccharides in the α- configuration. These results were confirmed by two-dimensional nuclear magnetic resonance (HSQC), with a single C1/H1, in 99.2/4.98 ppm, typical of one α bonding, and low-field 82.6/3.55 ppm signal displacement, characteristic of substituted C-3, indicating that EPS is an α-(1→3)-glucan. Sulfation of this molecule resulted in α- (1→3)-glucansulf with DS of 0.75 which was used in the anticoagulant activity assays. The increase in coagulation reaction time in the APTT (Activated Partial Thromboplastin Time) and TT (Thrombin Time) tests was concentration-dependent, indicating that [α-(1→3)-D-glucansulf] might act as an inhibitor of the intrinsic via of blood clotting and conversion of fibrinogen into fibrin, characterizing it as a potential anticoagulant.